B III Biography and Net Worth

Jack Henneman joined the Board in 2023 upon the completion of the merger with SeaSpine. Prior to the merger, Mr. Henneman had served on SeaSpine’s Board of Directors since July 2015. Mr. Henneman has more than 25 years of combined financial and operational management experience in the life sciences industry. From January 2019 to June 2024, Mr. Henneman was a partner with SparkMed Advisory LLC where he provided strategic, marketing, development, and transactional advice for start-ups and other innovators in the medical device and biotechnology industries. From March 2018 to November 2024, Mr. Henneman also served as a strategic advisor to Prettybrook Partners LLC, a private equity and venture capital firm specializing in investments in medical technology, healthcare services, and information technology. Previously, Mr. Henneman served as Executive Vice President and Chief Financial Officer of NewLink Genetics Corporation from October 2014 to July 2018, and as its Chief Administrative Officer from July 2018 to November 2018. NewLink Genetics, a public company that later merged into Lumos Pharma in 2020, was a biopharmaceutical company focused on discovering and developing novel immuno-oncology treatments to improve cancer care. Prior to NewLink, Mr. Henneman served at Integra LifeSciences Holdings in various capacities between 1998 and 2014. Before becoming Integra’s Chief Financial Officer in 2007, Mr. Henneman served as General Counsel and Chief Administrative Officer, responsible at various time for  Integra’s business development, regulatory affairs, quality systems, clinical affairs, human resources, information systems, and legal affairs functions and the management of Integra’s surgical instruments business. Integra is a public medical technology company, focusing on regenerative medicine, neurosurgical devices, and reconstructive surgery instruments, including artificial skin. Prior to Integra, Mr. Henneman served as General Counsel, Vice President of Corporate Development, and eventually Interim Co-Chief Executive Officer for Neuromedical Systems, Inc., a public company known for a computer-assisted screening tool for cytological specimens. Mr. Henneman also serves as a member of the board of directors of various public and private companies, including Aprea Therapeutics, Inc., since August 2019, a public biotechnology company; Anika Therapeutics, Inc., since September 2020, a public medical device company focused on joint preservation and health; and Alafair Biosciences, Inc., since January 2015, a privately held medical device company. From February 2016 to November 2024, Mr. Henneman also served as a member of the board of directors for R1 RCM, Inc., a public company providing revenue cycle management services to hospitals and physicians. He received a Bachelor of Arts in Politics from Princeton University and a Juris Doctor from University of Michigan Law School.